LAUSANNE, Switzerland, June 30, 2026
ADC Therapeutics SA has announced the successful completion of patient enrollment in the LOTIS-7 Phase 1b clinical trial, evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The milestone marks an important advancement in the company’s strategy to expand the clinical potential of its CD19-directed antibody-drug conjugate (ADC) through combination therapies aimed at improving outcomes for patients with aggressive B-cell malignancies. A total of 100 patients have now been enrolled and treated with the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab across 30 clinical sites in the United States and Europe, representing one of the largest studies evaluating this promising combination approach. Building on previously reported interim findings showing an overall response rate (ORR) of 89.8% and a complete response (CR) rate of 77.6%, the completed enrollment positions the company to deliver comprehensive efficacy and safety results later in 2026 while advancing discussions on potential regulatory pathways for the combination therapy.
LOTIS-7 Enrollment Milestone Strengthens Clinical Development
The LOTIS-7 Phase 1b trial is a global, multicenter, open-label study evaluating multiple combination regimens featuring ZYNLONTA® in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma. The completed enrollment specifically covers the ZYNLONTA® plus glofitamab treatment arm, where 100 patients received the selected therapeutic dose following successful dose-escalation studies. Approximately 70% of enrolled patients were treated in the United States, while 30% were enrolled across European clinical centers, with patient characteristics reflecting a challenging treatment population consisting of 46% relapsed disease and 54% primary refractory disease.
The study’s primary objectives focus on evaluating safety and tolerability, while secondary endpoints include overall response rate, complete response, duration of response, progression-free survival, relapse-free survival, overall survival, pharmacokinetics, and immunogenicity. Full clinical data from LOTIS-7 are expected during the fourth quarter of 2026, followed by presentation at a scientific meeting and submission for peer-reviewed publication.
Promising ADC and Bispecific Combination Targets Aggressive Lymphoma
Advertisement
ZYNLONTA® is a CD19-directed antibody-drug conjugate (ADC) designed to selectively target malignant B cells while delivering a potent pyrrolobenzodiazepine (PBD) payload that induces irreversible DNA damage and tumor cell death. The investigational combination pairs this targeted ADC with glofitamab, a CD20xCD3 bispecific antibody that redirects T cells to eliminate lymphoma cells through immune-mediated mechanisms. Previously reported interim data from LOTIS-7 demonstrated highly encouraging clinical activity, with an 89.8% overall response rate and 77.6% complete response rate among efficacy-evaluable patients after at least six months of follow-up, while maintaining a manageable safety profile.
These early findings suggest the combination has the potential to become one of the leading bispecific antibody-based treatment options for patients with relapsed or refractory diffuse large B-cell lymphoma, particularly for individuals who have exhausted conventional therapeutic approaches.
Combination Therapy Advances Future Lymphoma Treatment Options
The successful completion of enrollment further strengthens ADC Therapeutics’ leadership in antibody-drug conjugate development and supports its broader strategy of expanding ZYNLONTA® into earlier treatment settings and combination regimens. Already approved in both the United States and European Union for adults with relapsed or refractory large B-cell lymphoma following two or more prior systemic therapies, ZYNLONTA® continues to demonstrate growing clinical potential through ongoing research.
With comprehensive LOTIS-7 results anticipated later this year, the company plans to evaluate regulatory and clinical guideline pathways that could support broader adoption of the combination therapy. The enrollment milestone represents another significant step toward delivering more effective, targeted immuno-oncology treatments capable of improving survival outcomes for patients facing aggressive B-cell lymphomas while reinforcing the expanding role of antibody-drug conjugates in modern cancer care.
Source: ADC Therapeutics press release
